Drug Type Bispecific antibody |
Synonyms Anti-CD40/PD1 Bispecific antibody(Lyvgen Biopharma Co., Ltd), LVGN8325 |
Target |
Mechanism CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | - |